{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T13:02:51Z","timestamp":1774789371443,"version":"3.50.1"},"reference-count":74,"publisher":"Bentham Science Publishers Ltd.","issue":"39","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2019,3,14]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Colorectal cancer (CRC) is one of the most common causes of cancer-related death in the world. There\nis a document that angiotensin (AT) which is found to be involved in the progression of CRC. Furthermore, Angiotensin\nreceptor inhibitors (ARIs) and angiotensin-converting enzyme Inhibitors (ACE-Is) demonstrate activity\nin CRC by their inhibition of both Insulin-like growth factor 1 (IGF-1) and Vascular endothelial growth factor\n(VEGF), and therefore present a potentially novel therapeutic strategy in colorectal cancer, which have summarized\nin the current review. Preclinical studies have illustrated the direct effect of major active mediator angiotensin\nII (ATII) on the promotion of angiogenesis through VEGF and other proliferative mediators. Suppression\nof the angiotensin II type I receptor (AT1R) via ACE-Is has shown a reduction in the development of solid tumor\nand metastasis, particularly CRC incidence, polyp formation, and distant metastasis. MicroRNAs (miRs) are a\nfamily of small nucleotides without coding that plays an important role after transcribing hundreds to thousands\nof non-coding and coding gene. Against this background, the application of anti-hypertensive medications such as\nlosartan might have a therapeutic impact, although further preclinical and clinical studies might provide novel\ninsight into the potentially beneficial effect of ACE-Is in the treatment of colorectal cancer patients.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1381612825666190111145140","type":"journal-article","created":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T04:52:52Z","timestamp":1547441572000},"page":"4652-4658","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The Therapeutic Potential of Angiotensin-converting Enzyme and Angiotensin Receptor Inhibitors in the Treatment of Colorectal Cancer: Rational Strategies and Recent Progress"],"prefix":"10.2174","volume":"24","author":[{"given":"Fereshteh","family":"Asgharzadeh","sequence":"first","affiliation":[{"name":"Department of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Mahdi","family":"Hassanian","sequence":"additional","affiliation":[{"name":"Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon A.","family":"Ferns","sequence":"additional","affiliation":[{"name":"Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex BN1 9PH, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majid","family":"Khazaei","sequence":"additional","affiliation":[{"name":"Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malihe","family":"Hasanzadeh","sequence":"additional","affiliation":[{"name":"Department of Gynecology Oncology, Woman Health Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00432-015-1928-z","volume":"142","author":"Vatandoost N.","year":"2016","unstructured":"Vatandoost N, Ghanbari J, Mojaver M.  Early detection of colorectal cancer: from conventional methods to novel biomarkers.","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3748\/wjg.v22.i6.1925","volume":"22","author":"Bonnington S.N.","year":"2016","unstructured":"Bonnington SN, Rutter MD.  Surveillance of colonic polyps: Are we getting it right?","journal-title":"World J Gastroenterol"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s10552-015-0617-1","volume":"26","author":"Dai Y-N.","year":"2015","unstructured":"Dai Y-N, Wang J-H, Zhu J-Z, Lin J-Q, Yu C-H, Li Y-M.  Angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers therapy and colorectal cancer: A systematic review and meta-analysis.","journal-title":"Cancer Causes Control"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/002215540205000215","volume":"50","author":"Hirasawa K.","year":"2002","unstructured":"Hirasawa K, Sato Y, Hosoda Y, Yamamoto T, Hanai H.  Immunohistochemical localization of angiotensin II receptor and local renin-angiotensin system in human colonic mucosa.","journal-title":"J Histochem Cytochem"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nrc2945","volume":"10","author":"George A.J.","year":"2010","unstructured":"George AJ, Thomas WG, Hannan RD.  The renin-angiotensin system and cancer: old dog, new tricks.","journal-title":"Nat Rev Cancer"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1097\/MCG.0b013e3181ea1044","volume":"45","author":"Kedika R.","year":"2011","unstructured":"Kedika R, Patel M, Pena Sahdala HN, Mahgoub A, Cipher D, Siddiqui AA.  Long-term use of angiotensin converting enzyme inhibitors is associated with decreased incidence of advanced adenomatous colon polyps.","journal-title":"J Clin Gastroenterol"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/jcb.25903","volume":"118","author":"Bahrami A","year":"2017","unstructured":"Bahrami A, Amerizadeh F.   ShahidSales S, et a Therapeutic Potential of Targeting Wnt\/\u03b2-Catenin Pathway in Treatment of Colorectal Cancer: Rational and Progress.","journal-title":"J Cell Biochem"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.amjcard.2010.11.026","volume":"107","author":"Huang C-C.","year":"2011","unstructured":"Huang C-C, Chan W-L, Chen Y-C.  Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension.","journal-title":"Am J Cardiol"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1196\/annals.1414.011","volume":"1138","author":"Attoub S.","year":"2008","unstructured":"Attoub S, Gaben AM, Al-Salam S.  Captopril as a potential inhibitor of lung tumor growth and metastasis.","journal-title":"Ann N Y Acad Sci"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.gastro.2006.06.028","volume":"131","author":"Lang L.","year":"2006","unstructured":"Lang L.  ACE inhibitors may reduce esophageal cancer incidence.","journal-title":"Gastroenterology"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/pros.10294","volume":"58","author":"Ronquist G.","year":"2004","unstructured":"Ronquist G, Rodr\u00edguez LAG, Ruig\u00f3mez A.  Association between captopril, other antihypertensive drugs and risk of prostate cancer.","journal-title":"Prostate"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0002-9610(97)00275-4","volume":"175","author":"Wanner G.A.","year":"1998","unstructured":"Wanner GA, M\u00fcller P, Ertel W, Busch CJ, Menger MD, Messmer K.  Differential effect of cyclooxygenase metabolites on proinflammatory cytokine release by Kupffer cells after liver ischemia and reperfusion.","journal-title":"Am J Surg"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/01.RES.68.2.450","volume":"68","author":"Daemen M.J.","year":"1991","unstructured":"Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM.  Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall.","journal-title":"Circ Res"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2174\/1570161043385556","volume":"2","author":"Escobar E.","year":"2004","unstructured":"Escobar E, Rodr\u00edguez-Reyna TS, Arrieta O, Sotelo J.  Angiotensin II, cell proliferation and angiogenesis regulator: biologic and therapeutic implications in cancer.","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=15","first-page":"472","volume":"55","author":"Wu X.Z.","year":"2008","unstructured":"Wu XZ.  New strategy of antiangiogenic therapy for hepatocellular carcinoma.","journal-title":"Neoplasma"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s10585-012-9480-6","volume":"29","author":"Shimomoto T.","year":"2012","unstructured":"Shimomoto T, Ohmori H, Luo Y.  Diabetes-associated angiotensin activation enhances liver metastasis of colon cancer.","journal-title":"Clin Exp Metastasis"},{"key":"ref=17","first-page":"6726","volume":"63","author":"Yasumaru M.","year":"2003","unstructured":"Yasumaru M, Tsuji S, Tsujii M.  Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.","journal-title":"Cancer Res"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"10663","DOI":"10.1073\/pnas.92.23.10663","volume":"92","author":"Nakajima M.","year":"1995","unstructured":"Nakajima M, Hutchinson HG, Fujinaga M.  The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1172\/JCI117710","volume":"95","author":"Stoll M.","year":"1995","unstructured":"Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T.  The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells.","journal-title":"J Clin Invest"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1002\/1097-0142(20011101)92:9<2462::AID-CNCR1596>3.0.CO;2-L","volume":"92","author":"Friis S.","year":"2001","unstructured":"Friis S, S\u00f8rensen HT, Mellemkjaer L.  Angiotensin-converting enzyme inhibitors and the risk of cancer: A population-based cohort study in Denmark.","journal-title":"Cancer"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1470-2045(10)70106-6","volume":"11","author":"Sipahi I.","year":"2010","unstructured":"Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC.  Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials.","journal-title":"Lancet Oncol"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"djt438","DOI":"10.1093\/jnci\/djt438","volume":"106","author":"Song M.","year":"2014","unstructured":"Song M, Giovannucci EL.  Antihypertension and colorectal cancer prevention: getting two birds with one stone?","journal-title":"J Natl Cancer Inst"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1159\/000490834","volume":"47","author":"Zhang L.","year":"2018","unstructured":"Zhang L, He L, Zhang H, Chen Y.  Knockdown of MiR-20a Enhances Sensitivity of Colorectal Cancer Cells to Cisplatin by Increasing ASK1 Expression.","journal-title":"Cell Physiol Biochem"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.placenta.2010.11.004","volume":"32","author":"Goyal R.","year":"2011","unstructured":"Goyal R, Lister R, Leitzke A, Goyal D, Gheorghe CP, Longo LD.  Antenatal maternal hypoxic stress: Adaptations of the placental renin-angiotensin system in the mouse.","journal-title":"Placenta"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"30A","DOI":"10.1016\/j.amjcard.2009.10.009","volume":"105","author":"Hoogwerf B.J.","year":"2010","unstructured":"Hoogwerf BJ.  Renin-angiotensin system blockade and cardiovascular and renal protection.","journal-title":"Am J Cardiol"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s004180100313","volume":"116","author":"De Paepe B.","year":"2001","unstructured":"De Paepe B, Verstraeten VL, De Potter CR, Vakaet LA, Bullock GR.  Growth stimulatory angiotensin II type-1 receptor is upregulated in breast hyperplasia and in situ carcinoma but not in invasive carcinoma.","journal-title":"Histochem Cell Biol"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.cld.2008.07.013","volume":"12","author":"Moreno M.","year":"2008","unstructured":"Moreno M, Bataller R.  Cytokines and renin-angiotensin system signaling in hepatic fibrosis.","journal-title":"Clin Liver Dis"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1210\/me.2004-0536","volume":"20","author":"Hunyady L.","year":"2006","unstructured":"Hunyady L, Catt KJ.  Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II.","journal-title":"Mol Endocrinol"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s001090050360","volume":"77","author":"Blume A.","year":"1999","unstructured":"Blume A, Herdegen T, Unger T.  Angiotensin peptides and inducible transcription factors.","journal-title":"J Mol Med (Berl)"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/01.ATV.19.1.73","volume":"19","author":"Xi X-P.","year":"1999","unstructured":"Xi X-P, Graf K, Goetze S, Fleck E, Hsueh WA, Law RE.  Central role of the MAPK pathway in ang II-mediated DNA synthesis and migration in rat vascular smooth muscle cells.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3181\/00379727-210-43942","volume":"210","author":"Reddy M.K.","year":"1995","unstructured":"Reddy MK, Baskaran K, Molteni A.  Inhibitors of angiotensin-converting enzyme modulate mitosis and gene expression in pancreatic cancer cells.","journal-title":"Proc Soc Exp Biol Med"},{"key":"ref=32","first-page":"1073","volume":"7","author":"Yoshiji H.","year":"2001","unstructured":"Yoshiji H, Kuriyama S, Kawata M.  The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor.","journal-title":"Clin Cancer Res"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0140-6736(98)03228-0","volume":"352","author":"Lever A.F.","year":"1998","unstructured":"Lever AF, Hole DJ, Gillis CR.  Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?","journal-title":"Lancet"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0165-6147(00)89030-6","volume":"16","author":"Nahmias C.","year":"1995","unstructured":"Nahmias C, Strosberg AD.  The angiotensin AT2 receptor: searching for signal-transduction pathways and physiological function.","journal-title":"Trends Pharmacol Sci"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/carcin\/bgn171","volume":"29","author":"Ager E.I.","year":"2008","unstructured":"Ager EI, Neo J, Christophi C.  The renin-angiotensin system and malignancy.","journal-title":"Carcinogenesis"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/carcin\/23.7.1235","volume":"23","author":"Takagi T.","year":"2002","unstructured":"Takagi T, Nakano Y, Takekoshi S, Inagami T, Tamura M.  Hemizygous mice for the angiotensin II type 2 receptor gene have attenuated susceptibility to azoxymethane-induced colon tumorigenesis.","journal-title":"Carcinogenesis"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.canlet.2012.10.012","volume":"334","author":"Ishino K.","year":"2013","unstructured":"Ishino K, Mutoh M, Totsuka Y, Nakagama H.  Metabolic syndrome: A novel high-risk state for colorectal cancer.","journal-title":"Cancer Lett"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/ki.2008.358","volume":"74","author":"Billet S.","year":"2008","unstructured":"Billet S, Aguilar F, Baudry C, Clauser E.  Role of angiotensin II AT1 receptor activation in cardiovascular diseases.","journal-title":"Kidney Int"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.4161\/cbt.6.8.4412","volume":"6","author":"Carl-McGrath S.","year":"2007","unstructured":"Carl-McGrath S, Ebert MP, Lendeckel U, R\u00f6cken C.  Expression of the local angiotensin II system in gastric cancer may facilitate lymphatic invasion and nodal spread.","journal-title":"Cancer Biol Ther"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.tem.2005.07.009","volume":"16","author":"Deshayes F.","year":"2005","unstructured":"Deshayes F, Nahmias C.  Angiotensin receptors: A new role in cancer?","journal-title":"Trends Endocrinol Metab"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"e2697","DOI":"10.1136\/bmj.e2697","volume":"344","author":"Bhaskaran K.","year":"2012","unstructured":"Bhaskaran K, Douglas I, Evans S, van Staa T, Smeeth L.  Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database.","journal-title":"BMJ"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/sj.bjc.6604431","volume":"99","author":"Arrieta O.","year":"2008","unstructured":"Arrieta O, Pineda-Olvera B, Guevara-Salazar P.  Expression of AT1 and AT2 angiotensin receptors in astrocytomas is associated with poor prognosis.","journal-title":"Br J Cancer"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.1007\/s13277-015-3235-3","volume":"36","author":"Arrieta O.","year":"2015","unstructured":"Arrieta O, Villarreal-Garza C, Vizca\u00edno G.  Association between AT1 and AT2 angiotensin II receptor expression with cell proliferation and angiogenesis in operable breast cancer.","journal-title":"Tumour Biol"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.clinre.2011.06.008","volume":"35","author":"Beyazit Y.","year":"2011","unstructured":"Beyazit Y, Purnak T, Suvak B.  Increased ACE in extrahepatic cholangiocarcinoma as a clue for activated RAS in biliary neoplasms.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1172\/JCI16645","volume":"112","author":"Egami K.","year":"2003","unstructured":"Egami K, Murohara T, Shimada T.  Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth.","journal-title":"J Clin Invest"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/jcp.10313","volume":"196","author":"Greco S.","year":"2003","unstructured":"Greco S, Muscella A, Elia MG.  Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells.","journal-title":"J Cell Physiol"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nrneph.2013.251","volume":"10","author":"Roscioni S.S.","year":"2014","unstructured":"Roscioni SS, Heerspink HJL, de Zeeuw D.  The effect of RAAS blockade on the progression of diabetic nephropathy.","journal-title":"Nat Rev Nephrol"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0006-291X(02)00496-5","volume":"294","author":"Fujita M.","year":"2002","unstructured":"Fujita M, Hayashi I, Yamashina S, Itoman M, Majima M.  Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis.","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1440-1746.2006.04797.x","volume":"22","author":"Neo J.H.","year":"2007","unstructured":"Neo JH, Malcontenti-Wilson C, Muralidharan V, Christophi C.  Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases.","journal-title":"J Gastroenterol Hepatol"},{"key":"ref=50","first-page":"189","volume":"18","author":"Menter AR","year":"2017","unstructured":"Menter AR, Carroll NM, Sakoda LC.","journal-title":"Effect of angiotensin system inhibitors on survival in patients receiving chemotherapy for advanced non\u2013small-cell lung cancer Clinical lung cancer"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00432-009-0587-3","volume":"135","author":"Wilop S.","year":"2009","unstructured":"Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R, Jost E.  Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy.","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"e887","DOI":"10.1097\/MD.0000000000000887","volume":"94","author":"Aydiner A.","year":"2015","unstructured":"Aydiner A, Ciftci R, Sen F.  Renin-Angiotensin system blockers may prolong survival of metastatic non-small cell lung cancer patients receiving erlotinib.","journal-title":"Medicine (Baltimore)"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/MPA.0b013e3181c314cd","volume":"39","author":"Gong Q.","year":"2010","unstructured":"Gong Q, Davis M, Chipitsyna G, Yeo CJ, Arafat HA.  Blocking angiotensin II Type 1 receptor triggers apoptotic cell death in human pancreatic cancer cells.","journal-title":"Pancreas"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/cas.13423","volume":"109","author":"Nakamura K.","year":"2018","unstructured":"Nakamura K, Yaguchi T, Ohmura G.  Involvement of local renin-angiotensin system in immunosuppression of tumor microenvironment.","journal-title":"Cancer Sci"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/jgh.13307","volume":"31","author":"Nguyen L.","year":"2016","unstructured":"Nguyen L, Ager EI, Neo J, Christophi C.  Regulation of colorectal cancer cell epithelial to mesenchymal transition by the renin angiotensin system.","journal-title":"J Gastroenterol Hepatol"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1471-2407-10-134","volume":"10","author":"Neo J.H.","year":"2010","unstructured":"Neo JH, Ager EI, Angus PW, Zhu J, Herath CB, Christophi C.  Changes in the renin angiotensin system during the development of colorectal cancer liver metastases.","journal-title":"BMC Cancer"},{"key":"ref=57","first-page":"43","volume":"47","author":"Shimizu Y","year":"2017","unstructured":"Shimizu Y, Amano H, Ito Y.","journal-title":"The role of angiotensin II in liver metastasis formation from colorectal cancer The Kitasato medical journal"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1158\/1078-0432.CCR-14-0209","volume":"20","author":"Dougherty U.","year":"2014","unstructured":"Dougherty U, Mustafi R, Sadiq F.  The renin-angiotensin system mediates EGF receptor-vitamin d receptor cross-talk in colitis-associated colon cancer.","journal-title":"Clin Cancer Res"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/annonc\/mdw060","volume":"27","author":"Jones M.R.","year":"2016","unstructured":"Jones MR, Schrader KA, Shen Y.  Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer.","journal-title":"Ann Oncol"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/SLA.0000000000001626","volume":"264","author":"Cardinale D.","year":"2016","unstructured":"Cardinale D, Sandri MT, Colombo A.  Prevention of Atrial Fibrillation in High-risk Patients Undergoing Lung Cancer Surgery: The PRESAGE Trial.","journal-title":"Ann Surg"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","volume":"2","author":"Boekhout A.H.","year":"2016","unstructured":"Boekhout AH, Gietema JA, Milojkovic Kerklaan B.  Angiotensin II\u2013receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: A randomized clinical trial.","journal-title":"JAMA Oncol"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1161\/CIRCULATIONAHA.110.007336","volume":"123","author":"Pasternak B.","year":"2011","unstructured":"Pasternak B, Svanstr\u00f6m H, Callr\u00e9us T, Melbye M, Hviid A.  Use of angiotensin receptor blockers and the risk of cancer.","journal-title":"Circulation"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.15537\/smj.2015.10.12458","volume":"36","author":"Wang H-B.","year":"2015","unstructured":"Wang H-B, Yang J.  The role of renin-angiotensin aldosterone system related micro-ribonucleic acids in hypertension.","journal-title":"Saudi Med J"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"e96338","DOI":"10.1371\/journal.pone.0096338","volume":"9","author":"Hu B.","year":"2014","unstructured":"Hu B, Song JT, Qu HY.  Mechanical stretch suppresses microRNA-145 expression by activating extracellular signal-regulated kinase 1\/2 and upregulating angiotensin-converting enzyme to alter vascular smooth muscle cell phenotype.","journal-title":"PLoS One"},{"key":"ref=65","author":"Okada H.","year":"2012","unstructured":"Okada H.","journal-title":"Angiotensin Converting Enzyme Inhibitor\u2013Modulated MicroRNAs Targeting Renal Fibrosis"},{"key":"ref=66","author":"Pacurari M","year":"2015","unstructured":"Pacurari M, Tchounwou PB.","journal-title":"Role of MicroRNAs in renin-angiotensin-aldosterone system-mediated cardiovascular inflammation and remodeling International journal of inflammation"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/1470320313503693","volume":"15","author":"Yang L.X.","year":"2014","unstructured":"Yang LX, Liu G, Zhu GF.  MicroRNA-155 inhibits angiotensin II-induced vascular smooth muscle cell proliferation.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gene.2012.12.009","volume":"532","author":"Elton T.S.","year":"2013","unstructured":"Elton TS, Selemon H, Elton SM, Parinandi NL.  Regulation of the MIR155 host gene in physiological and pathological processes.","journal-title":"Gene"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.21873\/anticanres.11142","volume":"36","author":"D\u2019Angelo B.","year":"2016","unstructured":"D\u2019Angelo B, Benedetti E, Cimini A, Giordano A, Benedetti E, Cimini A, Giordano A.  MicroRNAs: A puzzling tool in cancer diagnostics and therapy.","journal-title":"Anticancer Res"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1186\/s40064-016-3425-5","volume":"5","author":"Fan T.","year":"2016","unstructured":"Fan T, Wang W, Zhang B.  Regulatory mechanisms of microRNAs in lung cancer stem cells.","journal-title":"Springerplus"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.biopha.2016.06.006","volume":"83","author":"Fang H.","year":"2016","unstructured":"Fang H, Shuang D, Yi Z, Sheng H, Liu Y.  Up-regulated microRNA-155 expression is associated with poor prognosis in cervical cancer patients.","journal-title":"Biomed Pharmacother"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.bbrc.2010.08.067","volume":"400","author":"Zheng L.","year":"2010","unstructured":"Zheng L, Xu C-C, Chen W-D.  MicroRNA-155 regulates angiotensin II type 1 receptor expression and phenotypic differentiation in vascular adventitial fibroblasts.","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ygyno.2012.04.020","volume":"126","author":"Choi C.H.","year":"2012","unstructured":"Choi CH, Park Y-A, Choi J-J.  Angiotensin II type I receptor and miR-155 in endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells.","journal-title":"Gynecol Oncol"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/SLA.0000000000001626","volume":"264","author":"Cardinale D.","year":"2016","unstructured":"Cardinale D, Sandri MT, Colombo A.  Prevention of Atrial Fibrillation in High-risk Patients Undergoing Lung Cancer Surgery: The PRESAGE Trial.","journal-title":"Ann Surg"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/168908","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/168908\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/168908","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,25]],"date-time":"2020-12-25T19:54:33Z","timestamp":1608926073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/168908\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,14]]},"references-count":74,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2019,3,14]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612825666190111145140","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3,14]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-11-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}